The risk of transmission of porcine microorganisms is, in addition to the immunological rejection and the physiological incompatibilities, a major hurdle to the clinical use of pig cells, tissues, and organs for the treatment of organ failure in humans, to overcome the medical need caused by the increasing lack of human donors.
Whereas most of the porcine microorganisms may be eliminated by early weaning, colostrum deviation, vaccination, antiviral drugs, animal isolation, cesarean delivery of newborns, and embryo transfer, porcine endogenous retroviruses (PERVs) cannot be eliminated this way because they are integrated in the genome of all pigs. 1 Only a few years before evidence was published that PERV is able to infect human cells, 2 two other retroviruses, simian immunodeficiency virus of chimpanzees (SIVcpz), and simian immunodeficiency virus from sooty mangabeys (SIVsm), now called human immunodeficiency viruses 1 and 2 (HIV-1 and 2), invaded the human population causing the fatal acquired immunodeficiency syndrome (AIDS).
3,4 Although
HIV and PERVs are not very closely related, the fact that PERV is a retrovirus makes it so difficult to evaluate its risk. 5 Also, although most retroviruses are immunosuppressive in the infected host, the absence of an animal model makes it difficult to show this for PERV. 6 In recent years, several strategies have been exploited to evalu- 
| INFEC TI ON E XPERIMENTS IN VITRO
There are three types of PERV, PERV-A and PERV-B which are present in the genome of all cells and which infect human cells (humantropic viruses), and PERV-C which is present in most, but not all pigs and infects only pig cells (ecotropic virus) (for review see Ref. [1] ). This means that PERV-A and PERV-B are able to infect different human cells and cell lines in vitro, in cell culture. 2 Recombinant viruses between PERV-A and PERV-C (PERV-A/C), able to infect human cells and characterized by a high replication rate, been have described. 1 Some human cell lines such as the 293 pig embryonic kidney cell line are highly susceptible, and after repeated passages of PERV through these human cells, the virus showed a higher replication rate and genetic changes in its long-terminal repeat (LTR). These viruses were called "human cell-adapted PERVs". 7 The lack of the restriction factor apolipoprotein B-editing catalytic polypeptide-like subunit (APOBEC) and transformation by DNA viruses are thought to be the reason for the high susceptibility of 293 cells. However, primary cells including porcine aortic endothelial cells (PAEC) and peripheral blood mononuclear cells (PBMCs) have also been infected. 8, 9 PBMCs can more effectively be infected with human cell-adapted PERVs; however, it remains unclear whether the virus infection is productive, for example, whether the virus infects cells and produces excess progeny. 10 In the case of PAEC, a productive infection including mRNA production and particle release has been demonstrated. 8 and no virus release. 12 Only after mitogenic stimulation of some pig PBMCs, virus particles were released that were able to infect human 293 cells. 12, 13 Therefore, these in vitro studies have only a limited relevance for the evaluation whether PERVs pose a risk for xenotransplantation (Table 1) .
| INFEC TI ON E XPERIMENTS IN VIVO
PERV-A and PERV-B infect not only human cells in vitro, but also cells of other species (polytropic viruses), with some exceptions such as mouse cells. 1, [14] [15] [16] [17] [18] Based on these results, numerous attempts have been undertaken to establish a small laboratory animal model of PERV infection (Table 1) . However, injection of PERV preparations into mice, rats, guinea pigs, and minks, with or without immunosuppression, failed to infect these animals. [15] [16] [17] [18] [19] Cells from NHPs could also be infected in vitro; however, in most cases, this did not result in a productive infection. 17, 19 In some cases, for example, chimpanzee cells, only human cell-adapted PERVs, were able to show infection. 20 When three NHP species, namely baboons, rhesus monkeys and pig-tailed monkeys, were inoculated with human cell-adapted PERV-A/C, and the animals were treated daily with three different immunosuppressive drugs (cyclosporine, everolimus (RAD), and methylprednisolone), no PERV infection was observed during a follow-up of more than 300 days.
17,21
Inoculation of rats with PERV or PERV-producing cells, 22 or pig islet cells, 16 as well as treatment of minks 18 or guinea pigs 22 with PERV did not result in infection. Only in guinea pigs, a transient infection was observed. 23 Mice could not be infected, 15,24 because mice lack a PERV receptor. 25 Noteworthy, early reports on PERV infection of SCID mice 26, 27 and athymic mice 28 proved to represent an artifact based on pseudotyping with endogenous murine retroviruses. 29, 30 Mice transgenic for the human PERV receptor huPAR-2 have been generated, and it was reported that they could be infected with PERV in vivo. 31 Although this is the only known in vivo model of PERV infection, no follow-up studies on pathogenic effects of the virus were published.
In rhesus and cynomolgus macaques, and baboons, the main virus receptor PAR-1 was found to be genetically deficient by a mutation at the same position as reported in mice, which is one explanation for the inefficient infection. 32 The receptor in African green monkeys does not have this mutation, but nevertheless the replication is quite low. 32 To summarize, all small laboratory animal and NHP model systems are not suitable to evaluate the risk posed by PERVs or to study PERV pathogenesis (Table 1) .
| PRECLINI C AL TRIAL S IN NHPS
In recent years, a number of pig-to-NHP preclinical xenotransplantation studies have been performed regarding hearts, kidneys, islet cells or studies performing perfusion of pig liver, under immunosuppression (for review, see Ref. [1] ). In all these studies, and also in more recent transplantations not listed in Ref. [1] , that is, studies on islet cell transplantation in marmosets 33 and cynomolgus monkeys, 34 no PERV transmission was observed. However, as the PERV receptor in NHPs is not functional, these results cannot be used to evaluate the safety of xenotransplantation using pig cells and organs (Table 1) . Hence, it does not make sense to include the monitoring for PERV transmission in pivotal nonclinical trials before phase transition to clinical development.
Interestingly, some regulatory agencies require such studies, which are elaborate and time-consuming, and essentially not informative.
| CLINIC AL TRIAL S
In the past, more than 200 humans have received a xenotransplantation product comprising pig cells, or tissues including ex vivo perfusion of pig organs or pig cell-based bioreactors, 35, 36 
reviewed in Refs
[1] and [37] . No evidence for virus transmission was obtained using During the last years, further clinical trials have been performed, including the first prospective clinical trials under proper regulatory oversight using encapsulated pig islet cells to treat type one diabetes in New Zealand 38 and Argentina. 39 Although the clinical efficacy in these trials was limited, no PERV transmission has been observed. 40, 41 In all of these porcine islet clinical trials, no immunosuppression was given and the islet cells were transplanted encapsulated in biopolymers, a procedure which protects from host′s humoral and cellular immune system (immunoglobulins and immune cells), but also which prevents release of PERVs (Table 1) . After some pioneering explorations more than 40 years ago, transplantation of a large vascularized organ accompanied by an effective pharmaceutical immunosuppression has still not been performed. (HERVs) has not been reported. 47 Furthermore, off-target effects by CRISPR/Cas9 may happen, but they will be detected when analyzing the health of the animals, and animals with defects will be eliminated.
| PER S PEC TIVE S
Therefore, two options for the first solid organ xenotransplantations could be foreseen. First, the use of organs from conventional, non-CRISPR/Cas9-treated animals in well-controlled trials, for example, using pigs with the absence of PERV-C, low copy number and low expression of PERV-A and PERV-B. Monitoring of the xenotransplant recipient would be as proposed by regulatory agencies 48 using highly sensitive PCR-based and immunological methods.
Alternatively, pigs with CRISPR/Cas9-inactivated PERVs could be used. The monitoring might in first instance be similar as mentioned above, considering that the sense of the gene editing cannot be demonstrated in in vivo animal models. 44 Additional strategies to prevent PERV transmission have been considered such as a vaccine based on neutralizing antibodies [49] [50] [51] [52] and antiretroviral drugs (for review see Ref. [53] ), which may be used should a positive detection of PERV occur. With this in mind, it seems feasible to go ahead with conventional animals as has been performed in many trials before. 
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